Diastolic Deceleration Area in Early-onset FGR

NCT ID: NCT05820464

Last Updated: 2023-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-04-19

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DDA is a new Doppler parameter aiming to assess fetal well-being in-utero. Early-onset SGR is a specific subgroup of fetuses where the clinical application of this Doppler modality could play an important role in the detection of hypoxia, anemia, and brain-sparing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypoxia Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Standard care:

* Doppler velocimetry: UA \& MCA PI, DV PIV, CPR;
* Indirect cardiotocography (CTG)
* Biophysical profile (BPP)

No interventions assigned to this group

DDA Doppler group

Standard care plus DDA Doppler monitoring

DDA Doppler

Intervention Type DIAGNOSTIC_TEST

A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DDA Doppler

A new Doppler parameter to quantify the amount of vasodilatation in the middle cerebral artery (MCA) and other blood vessels.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* absence of fetal abnormalities and/or genetic conditions;
* single pregnancy;
* fetal growth restriction (FGR) \< 10%, according to the INTERGROWTH 21st nomograms, appearing before 32nd week of gestation

Exclusion Criteria

* documented fetal abnormalities and/or genetic conditions in the course of the pregnancy;
* multiple pregnancy;
* absence of fetal growth restriction (FGR) \< 10%, according to the INTERGROWTH 21st nomograms before 32nd week of gestation
Minimum Eligible Age

18 Years

Maximum Eligible Age

48 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Orthogyn Medical Center, Bulgaria

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Petar Ignatov

Assoc. prof. Petar Ignatov, M.D., Ph. D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Petar N Ignatov, PhD

Role: PRINCIPAL_INVESTIGATOR

Orthogyn Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orthogyn Medical and Dental Center

Sofia, , Bulgaria

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Bulgaria

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Petar N Ignatov, PhD

Role: CONTACT

+359888963189

Teodora B Yordanova-Ignatova, PhD

Role: CONTACT

+359888226360

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Petar N Ignatov

Role: primary

0888963189

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DDA1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.